Guidelines for the Diagnosis and Management of Hereditary Spherocytosis

The British Committee for Standards in Haematology

Address for correspondence:

Dr. Paula Bolton-Maggs
c/o BCSH Administrator
British Society for Haematology
100 White Lion Street
London N1 9PF
Email: bcsh@b-s-h.org.uk

Writing Group:
Paula H.B. Bolton-Maggs¹, Jacob C. Langer², Achille Iolascon³, Paul Tittensor⁴, May-Jean King⁵

Disclaimer:
While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society for Haematology nor the publishers accept any legal responsibility for the content of these guidelines.

Date of publication: September 2011
BCSH reviews its guidelines on a regular basis and should new evidence come to light or expert opinion on best practice change, the guideline will be updated or amended accordingly.

¹University of Manchester, UK
²University of Toronto, Hospital for Sick Children, Toronto, Canada
³University Federico II of Naples, Naples, Italy
⁴Patient representative, Crewe, Cheshire
⁵NHS Blood and Transplant, Bristol
Table of Contents

Introduction and methodology........................................................................................................3

Summary of key recommendations...................................................................................................4

1. Biochemical basis of HS .............................................................................................................6

2. Clinical features and diagnosis ..................................................................................................9

3. Laboratory investigation.............................................................................................................12

4. Clinical management ................................................................................................................16

5. Conclusions .............................................................................................................................24

Acknowledgements and declarations of interest ............................................................................25

Appendix 1: Grades of evidence and strength of recommendations ............................................20

References .......................................................................................................................................27

Table 1: Types of mutation and observed defects ...........................................................................34

Table 2: Classification of spherocytosis and indications for splenectomy .......................................35

Table 3: Application of screening tests ..........................................................................................36

Figure 1: Schematic presentation of the red cell cytoskeleton .......................................................37

Figure 2: Flowchart for diagnosis of HS .........................................................................................38
Introduction and methodology
The guideline group was selected to represent UK medical experts and patients representatives but sought the expertise of two overseas specialists with a particular interest in hereditary spherocytosis. The writing group searched PubMed from 2003 to July 2010 for relevant literature including meta-analyses (none found), reviews and original papers in any language, using the following key words and combinations of them: hereditary spherocytosis; red cell membrane; spectrin; ankyrin; band 3; spherocytes; haemolysis; folate; folic acid; splenectomy; cholecystectomy; cholecystostomy; laparoscopic; gallstones; pneumococcal; vaccination; penicillin prophylaxis. Only the abstracts were read of papers in languages other than English. The writing group produced the draft guideline which was subsequently revised by consensus by members of the General Haematology Task Force of the British Committee for Standards in Haematology (BCSH). The guideline was then reviewed by a sounding board of approximately 50 UK haematologists, the BSCH and the British Society for Haematology Committee and comments incorporated where appropriate. The ‘GRADE’ system was used to quote levels and grades of evidence, details of which can be found in the appendix. The objective of this guideline is to provide healthcare professionals with clear guidance on the management of hereditary spherocytosis. In all cases individual patient circumstances may dictate an alternative approach.

Guidelines on hereditary spherocytosis (HS) published in 2004 (Bolton-Maggs, et al 2004) are here replaced to reflect changes in current opinion on the surgical management, (particularly the indications for concomitant splenectomy with cholecystectomy in children with mild HS, and concomitant cholecystectomy with splenectomy in those with asymptomatic gallstones). Further potential long term hazards of splenectomy are now recognised. Advances have been made in our understanding of the biochemistry of the red cell membrane which underpins the choice of tests. Biochemical assays of membranes proteins and genetic analysis may be indicated (rarely) to diagnose atypical cases. The diagnostic value of the
eosin-5-maleimide (EMA) binding test has been validated in a number of studies with understanding of its limitations.

Summary of Key Recommendations

Diagnostic testing (*confirmation of the 2004 guidelines*)

- Newly diagnosed patients with a family history of HS, typical clinical features and laboratory investigations (spherocytes, raised MCHC, increase in reticulocytes) do not require any additional tests (1A).
- If the diagnosis is equivocal, a screening test with high predictive value for HS is helpful. The recommended screening tests are the cryohemolysis test and EMA binding (1A).
- Gel electrophoresis analysis of erythrocyte membranes is the method of choice for diagnosis of atypical cases.

Recommendations for surgery (*updated with major changes since the 2004 guidelines*)

- The laparoscopic approach to splenectomy is recommended, but is dependent on the availability of appropriately trained surgeons, and suitable equipment (1B).
- Partial splenectomy may be beneficial but needs further follow up studies (2C).
- In children undergoing splenectomy, the gall bladder should be removed concomitantly if there are symptomatic gallstones. If stones are an incidental finding without symptoms, the value of cholecystectomy remains controversial. If the gallbladder is left *in situ*, including cases when a cholecystostomy with stone extraction is done, close follow-up using ultrasound is necessary (2C).
- In children who require cholecystectomy for symptoms of gallstones, the use of concurrent splenectomy is controversial. It may be associated with a decreased future risk of common bile duct
stones, but is associated with a risk of post-splenectomy sepsis (2C).

- When splenectomy is indicated, ideally it should be done after the age of 6 years (2C).
- There is no indication for extended thrombosis prophylaxis after splenectomy in patients with HS. Adults should receive perioperative thromboprophylaxis in the usual way.
- Splenectomy should be avoided in patients with some forms of hereditary stomatocytosis due to an increased risk of venous thromboembolism (1B).

Key Words
Spherocytosis, hereditary; splenectomy; child; erythrocyte membrane
1. THE BIOCHEMICAL BASIS OF HS

Hereditary spherocytosis is a disease involving five membrane proteins that are in close contact with each other in the red cell membrane.

1.1 Organisation of red blood cell membrane

The human red cell membrane consists of an outer lipid bilayer (cholesterol and phospholipids) and an inner layer of cytoplasmic spectrin-based cytoskeleton (covering about 65% of red cell surface). These two layers have no direct contact with each other (Fig. 1). The current working hypothesis is that the concerted movements of the lipid bilayer and cytoskeleton proteins in the vertical and horizontal directions regulate both the deformability and elasticity of RBCs in circulation. In addition to the known band 3 tetramer-ankyrin complex, a band 3-adducin-spectrin complex has recently been identified (Anong, et al 2009).

1.2 Biochemical abnormalities associated with HS

Detachment of the lipid bilayer from the spectrin-based cytoskeleton results in weakening of the vertical interaction, caused by either a deficiency or dysfunction of one or more of band 3, protein 4.2, ankyrin, and α and β spectrin proteins (Delaunay 2007, Perrotta, et al 2008). The subsequent reduction in surface-to-volume ratio results in spherocytic red cells, which are osmotically fragile and are selectively trapped in and removed by the spleen, which consequently plays a pivotal role in the clinical features of this disease. Single or combined protein deficiency in the red cells can be determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) (Table I). Patients with a severe single membrane protein deficiency or an imbalance with combined protein deficiencies (most commonly band 3 and ankyrin defects) exhibit more severe haemolytic anaemia (Rocha, et al 2010a). Partial spectrin deficiency is likely to cause a moderate to severe clinical phenotype when compared with reductions in other membrane proteins. The clinical expression of HS is relatively uniform within a given family, but disease severity varies considerably between families. In a recent study of 300 HS patients, spectrin deficiency was the most frequent membrane defect (based on SDS-polyacrylamide gel analysis and not DNA
analysis of membrane genes) in those diagnosed in childhood whereas band 3 deficiency was the one found most in patients diagnosed during adulthood (Mariani, et al. 2008). Gilbert syndrome (defined by a bilirubin concentration of 17-102 micromole/L) is a recognised cause of variability of hyperbilirubinaemia and gallstone formation within families. Determination of the UGT1 promoter polymorphism ((TA)7) is associated with increased bilirubin levels due to reduced transcription of the enzyme, and when inherited with HS may give a false impression of severity of haemolysis (Iolascon, et al. 1998). Compound heterozygosity for this can also increase the risk of developing gallstones in HS children (Miraglia del Giudice, et al. 1999, Rocha et al. 2010).

### 1.2.1 Isolated red cell disorders due to band 3 mutations in the anion transport domain

Mutations affecting the anion transport function of band 3 can exacerbate the clinical features of some HS patients whose severe chronic haemolytic anaemia is not compatible with the small reduction of band 3 protein detected by SDS-PAGE. This subset of HS patients is designated as ‘spherocytosis with low temperature leak’ (SphLTL) (Bruce, et al. 2005) and their band 3 mutations occur within exon 17 of SLC4A1 which encodes amino acids forming a part of the anion transport domain. The red cells from SphLTL patients have a concomitant reduction in monovalent cation (Na+/K+) transport because the mutant band 3 protein becomes an unregulated cation transporter (Bruce 2008). Some patients in this subset may also have pseudohyperkalaemia.

### 1.3 Molecular genetics of HS

The genes encoding membrane proteins of the red cell cytoskeleton and their respective chromosomal locations are known (Table I). Autosomal dominant HS is often found to have primary mutations in the genes encoding ankyrin, band 3 or β spectrin. Mutations in these three genes can lead to a secondary protein deficiency. Protein 4.2 gene mutations are more prevalent among the Japanese population.
Most of the reported protein gene mutations in HS are “private” or sporadic occurrences, i.e., they are specific to one family or found in a few families from different countries. Knowledge of the gene mutation does not influence the clinical management of the patient but analysis of mutant protein gene in family studies can clarify one of the following conditions.

The $\text{Sp}^\alpha_{\text{LEPRA}}$ allele (LEPRA: Low Expression PRAgue) is prevalent among non-dominant HS (nd-HS) (Boivin, et al 1993, Dhermy, et al 2000, Wichterle, et al 1996). This allele remains silent when inherited by a normal individual. However, mutations in the $\alpha$ spectrin gene ($\text{SPTA1}$), both homozygous and compound heterozygous (co-inherited with a pathogenic HS allele), result in severe HS with very low spectrin levels in the red cells (Tse, et al 1997).

De novo mutations are mostly found in recessive HS associated with ankyrin gene ($\text{ANK}-1$) and $\beta$ spectrin ($\text{SPTB}$). The transmission of these ankyrin mutations to subsequent generations occurs in a dominant manner. A recurrent frameshift mutation, Ankyrin Florianópolis, has been found in three unrelated probands with severe dominant HS from different genetic backgrounds (Gallagher, et al 2000).

2. CLINICAL FEATURES AND DIAGNOSIS

The clinical severity of HS varies from symptom-free carrier to severe haemolysis. Mild HS can be difficult to identify because individuals may have normal haemoglobin and bilirubin concentrations. The presence of spherocytes and a reticulocytosis will support the diagnosis. If there are no spherocytes seen on the film, no abnormalities in the red cell indices, and the reticulocyte count is normal a ‘carrier’ state cannot be excluded, but the individual is unlikely to have any clinical sequelae. Occasionally mild HS can be exacerbated by illnesses that cause splenomegaly, such as infectious mononucleosis. It is important to consider other possible diagnoses for chronic haemolysis if the blood smear appearances are not typical, particularly congenital dyserythropoietic anaemia type II (CDA-II). Several cases have been misdiagnosed in the past with the correct diagnosis being established only when they fail to respond as expected to splenectomy (Iolascon, et al 2001).

2.1 Age at Diagnosis

Although the diagnosis of HS is often made in childhood and young adult life, it may be diagnosed at any time of life including old age (Bolton-Maggs, et al 2004).

2.2 Clinical features:

The diagnosis of HS is generally straightforward (Bolton-Maggs, et al 2004).

2.2.1. Diagnosis in the neonate

Neonatal jaundice is common and may require exchange transfusion, but is not clearly related to the subsequent severity of the HS. The diagnosis of HS in neonates may be difficult (Schroter 1983). The film appearances may not be typical, and the osmotic fragility test (OF) is unreliable. New studies show that an MCHC of greater than 360 g/l in neonates is a useful indicator for hereditary spherocytosis (82% sensitivity and 98% specificity) (Christensen and Henry 2010). The use of tests for red cell dehydration and reduced red cell deformability
demonstrated that four in 402 jaundiced neonates had HS (Saada, et al 2006), suggesting a higher HS incidence (1%) among this selected group of neonates with jaundice than the reported incidence for a general population (1 in 2000 to 1 in 5000). The mechanism for this is not clearly understood but the inability of HbF to bind the free 2,3-DPG may cause a destabilising effect of 2,3-DPG on the spectrin–protein 4.1 interaction (Pinto, et al 1995). Haematologists need to advise potential parents of the risk of neonatal jaundice, as occasionally exchange transfusion has been required for severe hyperbilirubinaemia. There may be an interval of several days before the bilirubin reaches its peak, so infants born to parents with known HS should be carefully monitored over several days.

Some neonates with HS may be transfusion-dependent due to their inability to mount an adequate erythropoietic response in the first year of life (Delhommeau, et al 2000). Continued transfusion-dependence is unusual and it is important to avoid repeated transfusion where possible. Erythropoietin may be of benefit in reducing or avoiding transfusion, and can usually be stopped by the age of 9 months (Tchernia, et al 2000). Many older children with Hb levels of 50-60 g/l do not require transfusion. Children requiring one or two transfusions early in life frequently become transfusion independent.

As the morphology may be unclear in the neonate, other diagnoses may be considered (Bolton-Maggs, et al 2004). Infantile pyknocytosis should be considered when an infant (usually pre-term) presents with transient haemolytic anaemia (6-9 months after birth), reticulocytosis and hyperbilirubinaemia. The blood film shows distorted densely stained red cells (pyknocytes). After blood transfusion, the transfused normal red cells may become distorted (Eyssette-Guerreau, et al 2006, Tuffy, et al 1959). This transient haemolytic anaemia of no known aetiology resolves 6 to 9 months after birth without further intervention.
Congenital dyserythropoietic anaemia type II (CDAII) (recessive inheritance with haemolysis with increased osmotic fragility) should be considered in the differential diagnosis because it may be misdiagnosed as HS and does not respond as satisfactorily to splenectomy.

2.2.2. **Co-inheritance of other haematological disorders.**

Other haematological disorders such as beta thalassaemia trait or sickle cell disease, can lead to confusion in the diagnosis and variable clinical effects. Iron, folate or B12 deficiency can mask the laboratory features. Obstructive jaundice alters the lipid composition of the red cell membrane, masking the red cell morphology, and reducing haemolysis.

2.2.3. **Family history:**

Most cases (75%) will have a family history of HS. In clear-cut cases (typical history and physical findings, spherocytes on the blood film with a reticulocytosis and negative direct antiglobulin test) there is no indication to perform further special laboratory tests. In the absence of a family history the most important differential diagnosis is autoimmune haemolysis (AIHA) (rare in children, but can follow a viral infection and is usually transient). Usually (but not always) AIHA can be excluded by a negative direct antiglobulin test. Other membrane abnormalities must be considered if the morphology is atypical, and in these, further investigations may be required.

2.3 **Individual clinical features**

2.3.1 **Anaemia**

The severity of anaemia reflects the severity of haemolysis and spleen size. Many individuals have compensated haemolysis with a normal haemoglobin concentration (Hb) but a reticulocytosis. During pregnancy some non-splenectomised HS patients develop sufficiently severe anaemia to need blood transfusion.
Erythropoietin may be of benefit in reducing or avoiding transfusion in neonates and can usually be stopped by the age of 9 months (Tchernia, et al 2000). Older individuals have an erythropoietin level higher than normal (Rocha, et al 2005). Many older children with Hb levels of 50-60 g/l do not require transfusion. Children requiring one or two transfusions early in life frequently become transfusion independent.

2.3.2. Splenomegaly

Most children and adults with HS have mild to moderate enlargement of the spleen, but other than assisting in the diagnosis, this is of little clinical significance. The size of the spleen per se is not an indication for splenectomy. There is no evidence from the literature that splenic rupture is commoner than in the normal population. There is also no evidence in support of limiting activity in children with splenomegaly due to HS.

Criteria for disease severity have been previously defined (Eber, et al 1990) and are shown in Table 2.

3. LABORATORY INVESTIGATION

The laboratory diagnosis is usually straightforward and is based upon a combination of clinical history, family history, physical examination (splenomegaly, jaundice) and laboratory data (full blood count, morphology and reticulocyte count) (Bolton-Maggs, et al 2004, Table IV). Additional testing for confirmation of HS is indicated when the diagnostic criteria are not met, and other causes of haemolysis have been excluded. For instance, the film appearances are atypical, there is no clear pattern of inheritance, or the proband has an on-going mild haemolytic process with an apparently normal full blood count.
The recommended laboratory tests are the eosin-5-maleimide (EMA) binding test or the cryohemolysis test. The osmotic fragility test is not recommended for routine use (Bolton-Maggs, et al 2004).

### 3.1 Eosin-5-maleimide binding test and other useful screening tests

The EMA binding test uses flow cytometry to determine the amount of fluorescence (reflecting EMA bound to specific transmembrane proteins) derived from individual red cells (King, et al 2004). If the majority of the patient's red cells are phenotypically normal without significant loss of the EMA-binding membrane proteins (as in the case of mildly affected HS), the fluorescence results obtained may be indeterminate. Such individuals are more easily identified in a family study. The question is whether these near-normal results are of any clinical significance. The EMA binding test is easy to use, and test results are available for reporting in 2-3 hours. It has comparable specificity and sensitivity to the acidified glycerol lysis test (Stoya, et al 2006) and ektacytometry (a test not readily available) (Girodon, et al 2008) and is better than OF (Kar, et al 2010).

In a general laboratory, the EMA binding test can be used in differential diagnosis for hereditary stomatocytoses (used in conjunction with OF) and hereditary pyropoikilocytosis (HPP, severe hereditary elliptocytosis) (Table 3). If the test results are consistent with the clinical presentation, there is the choice of whether or not to proceed with confirmatory tests (carried out by specialised laboratories).

When HS is suspected in a neonate, if the baby is well testing can be postponed until the child is at least 6 months of age or older when the morphology may be less confusing. The EMA test will be positive irrespective of morphology and age of the neonate. Other membrane abnormalities must be considered if the morphology is atypical, and in these, further investigations may be required. The reticulocyte count in CDAII is not as high as in HS. SDS-PAGE of red cell membrane proteins reveals the characteristic compact CDAII band 3 protein abnormality. This differential diagnosis is important because in CDAII
splenectomy is less effective and does not completely resolve the clinical symptoms.

Several laboratory tests can detect typical HS (Table 3). However, these can give false positive results for a wide spectrum of clinical conditions and rare red cell disorders unrelated to cytoskeleton defects (Bolton-Maggs, et al 2004, Table VI). Therefore caution is required when a positive test result for HS is not compatible with the clinical presentation and red cell morphology.

A normal OF does not exclude the diagnosis of HS and may occur in 10-20% of cases (Bolton-Maggs, et al 2004).

The acid glycerol lysis test (AGLT) has a higher detection rate in asymptomatic relatives of known affected individuals than the OF (Mariani, et al 2008). The drawback of both tests is an apparent lack of specificity under certain circumstances (Bolton-Maggs, et al 2004, Table VI). However, laboratories with long-standing experience in using the AGLT have found that the sensitivity can be greater than for the EMA binding test (Mariani, et al 2008).

3.2. Tests for differentiating HS from other rare membrane-associated disorders

These have been discussed in the previous guideline (Bolton-Maggs, et al 2004) and are summarised in Table 3.

Recommendations

- A suggested diagnostic pathway is shown in Figure 2

- Newly diagnosed patients with a family history of HS, typical clinical features (splenomegaly) and laboratory investigations (spherocytes, raised MCHC, increase in reticulocytes) do not require any additional tests (1A).
• If the diagnosis is equivocal, e.g. where there are a few spherocytes on the film but no other laboratory, clinical or family evidence, a screening test with high predictive value for HS is helpful. The recommended screening tests are the cryohemolysis test and EMA binding (1A). The high predictive value of both techniques for the diagnosis of HS can be improved further when the results are reviewed in conjunction with clinical information, family history and red cell indices. If the interpretation of the test result is still equivocal, perform a family study to determine the trend (i.e., which family members also give results similar to the proband).

• Confirmation of diagnosis may be necessary in selected cases if the screening tests produce an equivocal or borderline result. Gel electrophoresis analysis of erythrocyte membranes is the method of choice. This technique is useful for determining the extent of membrane deficiency for the patient. The main drawback is a lack of sensitivity to very mild or asymptomatic ‘carrier’ HS.

• The use of SDS-PAGE is recommended:
  a). When the clinical phenotype is more severe than predicted from the red cell morphology.
  b). When the red cell morphology is more severe than predicted from parental blood films where one parent is known to have HS.
  c). If the diagnosis is not clear prior to splenectomy, when a patient might have an abnormality in Na⁺/K⁺ permeability (as found in hereditary stomatocytosis).. Where the morphology and red cell indices are typical for HS, there should be no doubt. In more subtle cases (when MCV >100 fl) clarification is essential (Delaunay, et al 1999). Splenectomy may not be appropriate for the clinical management of those patients with the rare overhydrated and

- Diagnosis of HS does not require further investigation by molecular analysis of the affected genes.

### 4. CLINICAL MANAGEMENT OF INDIVIDUALS WITH HS

#### 4.1 Folate therapy
Folate supplementation is recommended in severe and moderate HS but is not necessary in mild HS. (Bolton-Maggs, *et al* 2004)

#### 4.2 Routine observation and frequency of blood tests
An annual visit for a child with HS is sufficient once the baseline has been established, and in the absence of symptoms a blood count at every visit is unnecessary. Growth should be monitored, and parents should be informed about the risk of sudden anaemia due to parvovirus infection. Children with severe HS should be closely monitored during other viral infections. Those receiving regular blood transfusions should have genotyped red cells. Adults with mild disease are not usually under regular follow up but chronic anaemia will enhance iron absorption and co-inheritance of a haemochromatosis gene can lead to severe iron overload.

#### 4.3 Clinical Management of individuals with HS – Surgery
This section has been significantly revised and replaces the recommendations in the previous guideline.

##### 4.3.1 In which patients is splenectomy indicated?
Splenectomy is very effective in reducing haemolysis, leading to a significant prolongation of the red cell life span (although not necessarily to normal) (Baird, *et al* 1971, Chapman and McDonald 1968) (Grade B evidence). The clinical
manifestations and complications (anaemia and gallstones) are much reduced in severe HS and abolished in milder cases but at the price of an increased risk of life-threatening sepsis from encapsulated organisms, particularly *Streptococcus pneumoniae*. Recent evidence demonstrates that splenectomy for hereditary spherocytosis in children is very safe in the short term with no deaths and infrequent complications (less than 1% in 1657 splenectomies) (Abdullah, et al 2009).

Patients should be selected for splenectomy on the basis of their clinical symptoms (Bolton-Maggs, et al 2004) Table 2, and presence of complications such as gallstones, not simply on the basis of the diagnosis alone (grade 2 recommendation, grade C evidence). Splenectomy should be performed in children with severe HS, considered in those who have moderate disease, and should probably not be performed in those with mild disease. A careful history is important in those with moderate to mild disease to establish if there is evidence suggesting reduced exercise tolerance; the metabolic burden of increased marrow turnover may be considerable. Where there is a family history, the benefit of splenectomy in other individuals may help determine whether to proceed.

### 4.3.2 Infection Risks and their management.
Splenectomy is associated with a lifelong increased risk of overwhelming infection, particularly with pneumococcal species, which is not completely eliminated by pre-operative vaccinations and post-splenectomy antibiotic prophylaxis (Bolton-Maggs, et al 2004). Patients should be vaccinated according to national guidelines (Davies, et al 2011). No changes are made in the recommendations (Bolton-Maggs, et al 2004). National recommendations vary and this subject has been recently reviewed (Price, et al 2007). It is important to keep searching for adults previously splenectomised (e.g. relatives of current HS patients) who are unlikely to have been fully protected (due to changes in
vaccination policy and emergence of more effective vaccines) and who may not know that they are at risk (Grace, et al 2009).

**Recommendations:**

- **Patients and parents should be informed about the lifelong small risk of overwhelming sepsis after splenectomy, and provided with a splenectomy card. (1B).**

- **National guidelines for immunisation should be followed (Davies, et al 2011). The need for reimmunisation and its frequency are unclear as are the optimal duration of postsplenectomy antibiotic prophylaxis and choice of drug (2C).**

**4.3.3 What surgical approach should be used?**

**Laparotomy:** The traditional approach to splenectomy has been total, by laparotomy, through either an upper midline incision or more usually a left subcostal approach. The spleen has been removed in its entirety and a careful search made for any splenunculi (accessory splenic tissue) on the assumption that any splenic tissue left behind could lead to a recurrence of symptomatic anaemia. There are no studies that have quantified this risk, although it has been reported (Mackenzie, et al 1962).

**Laparoscopic splenectomy:** The traditional approaches are being challenged by the advent of laparoscopy. Either a supine or lateral approach can be used, and the splenic vessels are divided using a harmonic scalpel, Ligasure™ device, clips or surgical stapler. The spleen is caught in a specimen bag introduced through a port site, and morcellated inside the bag so that the contents can be removed through the port. In cases of massive splenomegaly, the spleen may not fit into the bag and must be removed through an open incision. A transverse lower abdominal incision is usually used in this situation. Laparoscopic cholecystectomy may be performed at the same time (Farah, et al 1997). There
are no published randomised trials comparing laparoscopic to open splenectomy in children, though there are a large number of case series outlining experience with laparoscopic splenectomy, either on its own (Rescorla, et al 2002, Smith, et al 1994, Tanoue, et al 2002) (Minkes, et al 2000) or in combination with cholecystectomy (Caprotti, et al 1999). Each of these is a descriptive study and compares the outcomes of an institution’s experience against either historical data from the same institution or reported results from other institutions. Published results suggest that the laparoscopic approach is both feasible and safe (Danielson, et al 2000), and is associated with a shorter hospital stay, faster time to feeding, and less pain. Laparoscopic splenectomy is more difficult in the presence of significant splenic enlargement (Bagdasarian, et al 2000) so that a preoperative assessment of splenic size by ultrasound is recommended (Esposito, et al 1998). Laparoscopic splenectomy should be the preferred approach for surgeons who have the necessary equipment, training and experience to carry out these procedures safely.

**Partial splenectomy:** Concern over the possible consequences of sepsis has led some groups to investigate whether it is necessary to remove the whole spleen to control haemolysis. Partial splenectomy can improve transfusion-dependent children with very severe HS while theoretically preserving some splenic function as protection against sepsis (grade B evidence). A number of reports have been published (Bader-Meunier, et al 2001, Tchernia, et al 1997, Tchernia, et al 1993). Forty patients have been followed for 1 to 14 yrs and showed that the majority remained symptom free though 3 patients subsequently required total splenectomy for further symptomatic anaemia (Bader-Meunier, et al 2001), but only 17 of 40 patients had completed at least 5 years follow up and a further 5 were lost to follow up. It is too early to determine whether others will need total splenectomy. The phagocytic function of the spleen was sustained (demonstrated by technetium 99m scans) and there were no reports of serious infection. Because there is currently no accurate way to determine the ability of the spleen to participate in humoral defence, these patients were immunised and
continued on postoperative anti-bacterial prophylaxis. Another group have also reported favourable results in 16 children with HS followed for up to 6 years after partial splenectomy (Rice, et al 2003). Both of these series are small, and have been followed for too short a time to know if this procedure reduces risks of post-splenectomy sepsis. A further caution is that 4 of 18 patients developed new gallstones, after sub-total splenectomy. A recent larger multicentre study of 62 children documented excellent resolution of symptoms and improvement of anaemia, with fewer than 5% of the patients requiring subsequent completion splenectomy (Buesing, et al 2011).

Several groups have now reported the use of laparoscopic partial splenectomy in patients with HS, leaving behind either the upper or lower pole (Dutta, et al 2006, Vasilescu, et al 2006). In the short term, the postoperative course does not appear to be as favourable as seen with laparoscopic total splenectomy, in terms of pain management or hospital stay (Morinis, et al 2008). Longer follow-up will be necessary to determine if the outcomes after laparoscopic partial splenectomy are equivalent to those using an open technique.

4.3.4 Should a concurrent cholecystectomy be performed?
In children with no evidence of cholelithiasis, there is no indication to remove the gall bladder at the time of splenectomy. Once the spleen is removed, individuals with HS do not develop pigment stones. In the absence of stones, splenectomy alone is sufficient – a review of 17 patients who had undergone splenectomy without cholecystectomy (gall stones excluded pre- or peri-operatively) under the age of 18 years demonstrated that none developed any evidence of cholelithiasis (clinical or sub clinical) over a mean follow up of 15 years (Sandler, et al 1999).

Stones are reported to be present in 21% to 63% of patients with HS (Rutkow 1981). Symptoms of cholelithiasis remain a prime reason for carrying out a splenectomy in hereditary spherocytosis. A significant number of children with HS develop pigment stones in the first decade of life. The risk is increased in
individuals who co-inherit Gilbert syndrome with HS with a five-fold increased risk of developing gallstones (Miraglia del Giudice, et al 1999) (grade B evidence). An Italian survey of 468 children with HS showed that 79 had gallstones, about half of them diagnosed before the age of 11 years (Pinto, et al 1995). A study of 103 unsplenectomised children has shown that the pigmented stones seen in haemolytic diseases are radio-opaque in 50%, but ultrasound has an accuracy of 96%. Regular ultrasound examination of the biliary system from the age of about 5 years may identify individuals more likely to have troublesome symptoms later in life, and who may benefit from splenectomy prior to puberty (grade 2 recommendation, grade C evidence).

It is not clear whether adults with mild HS should be regularly screened by ultrasound for asymptomatic gallstones, particularly as it is not clear whether these should be removed. One study of 123 adults with silent stones (not in relation to haemolytic conditions) found that only 15-20% developed symptoms over a prolonged follow-up (Gracie and Ransohoff 1982). However, there are no good longitudinal studies of the outcome in children with silent stones if left alone. One study of children with non-pigmented stones suggested that asymptomatic stones should be managed expectantly (Bruch, et al 2000). Another study has shown chronic inflammatory changes in the gall bladder mucosa in individuals with asymptomatic stones (Csendes, et al 1998). There are no clear data on the management of asymptomatic gallstones in children undergoing splenectomy for HS. Some authors have suggested that all patients with stones, even the asymptomatic ones, should undergo cholecystectomy (Gotz, et al 1977), and this has become the most common approach by paediatric surgeons. However, there is evidence to suggest that in young children removal of stones without cholecystectomy may be sufficient after splenectomy. The rationale behind this is that the risk of stones is markedly reduced after splenectomy and there is evidence that cholecystectomy may lead to alterations in bile salt metabolism that predispose to colon carcinoma later in life (Shao and Yang 2005). Robertson (Robertson, et al 1988) reported on the
clinical and ultrasound follow up of 5 children with HS who had cholecystotomy with stone removal at the time of splenectomy. In 4 of the cases there were no stones, but in 1 there was an asymptomatic stone discovered. The follow up period however was short (1-2 years), and there have been no further reports of systematic follow up of this cohort. In both adults and children who do not undergo cholecystectomy, regular follow-up should include assessment of possible symptoms (typical and atypical) suggestive of gall bladder disease.

There is general consensus that individuals with symptomatic gallstones should undergo cholecystectomy, although there are no randomised trials examining this question. The opposite question, whether the spleen should be removed in children with mild HS who have symptomatic gallstones, remains controversial. A recent study of 16 children who had cholecystectomy without splenectomy for mild HS reported that only three subsequently required splenectomy (within 2.5 years). The follow up of the other 13 was 0.5 to 10.6 years (Alizai, et al 2010). This and other questions could be answered by well-designed observational studies, although they would have to be multi-centred.

Recommendations:

- The laparoscopic approach to splenectomy is associated with less pain, shorter hospital stay and better cosmetic appearance, but is dependent on the availability of appropriately trained surgeons, and suitable equipment (1B).
- Partial splenectomy is theoretically associated with a decreased risk for post-splenectomy sepsis, but it is possible that further surgery may need to be undertaken for either recurrence of haematological problems or for symptomatic cholelithiasis (2C).
- In children undergoing splenectomy, the gall bladder should be removed concomitantly if there are symptomatic gallstones. If stones are an incidental finding without symptoms, the value of cholecystectomy remains controversial. If the gallbladder is left in
situ (including when a cholecystostomy with stone extraction has been done), close follow-up using ultrasound is necessary (2C).

- In children who require cholecystectomy for symptoms of gallstones, the use of concurrent splenectomy is controversial. It may be associated with a decreased risk of common bile duct stones in the future, but is also associated with a risk of post-splenectomy sepsis (2C).
- When splenectomy is indicated, ideally it should be done after the age of 6 years (2C).

4.3.5 What is the risk of late post splenectomy thrombosis?

Adults undergoing splenectomy should receive standard thromboprophylaxis where indicated. Splenectomy is usually followed by a reactive thrombocytosis that may be quite spectacular in children, counts rising to more than 1000 x 10^9/l. (Boxer, et al 1978, Coon, et al 1978, Hirsh and Dacie 1966) Until recently, available evidence suggested that the only individuals in whom there is an increased risk of late (i.e. not related to the surgery itself) thrombosis after splenectomy were those with myeloproliferative disorders (Gordon, et al 1978), or persisting anaemia with abnormal red blood cells (Hirsh and Dacie 1966), demonstrated for beta thalassaemia intermedia (Cappellini, et al 2000) and for forms of hereditary stomatocytosis (Delaunay, et al 1999). It is therefore vital to differentiate these membrane disorders from HS and to avoid splenectomy. Thrombotic events have anecdotally been reported in patients with HS, (Hayag-Barin, et al 1998, Nikol, et al 1997) but the frequency of inherited thrombotic risk factors is high enough (particularly Factor V Leiden) in Northern Europeans that these will occur by chance in association with HS. However, there is now an increasing body of evidence (Crary and Buchanan 2009) that splenectomy may be associated with a number of vascular complications including pulmonary hypertension (Hoeper, et al 1999) and an increased risk of atherosclerosis (Schilling, et al 2006, Schilling, et al 2008). These factors should also be taken
into account when deciding whether or not to proceed to splenectomy (Schilling 2009).

**Recommendations:**

- **There is no indication for extended thrombosis prophylaxis after splenectomy in patients with HS. Adults should receive perioperative thromboprophylaxis in the usual way.**
- **Splenectomy should be avoided in patients with some forms of hereditary stomatocytosis (1B).**

**5. CONCLUSIONS**

New studies of the EMA binding test have confirmed its diagnostic validity for HS in many routine laboratories. For many years making the diagnosis was usually followed almost automatically by splenectomy. The indications for splenectomy are clearer and classification of HS into clinically mild, moderate and severe groups is helpful. Splenectomy will be of benefit in all people with severe and some people with moderate HS, but is not usually necessary in mild cases. Our recommendations concerning partial splenectomy and concomitant splenectomy with cholecystectomy or cholecystectomy with splenectomy have been updated to reflect current opinion but further studies are required. Recently evidence is emerging that there may be adverse vascular long term consequences of splenectomy. The final decision however, will rest on consultation between the family and clinician.
Acknowledgements:
Paula Bolton-Maggs led the guideline writing and was responsible for editing the manuscript. May-Jean King contributed the biochemical and laboratory section, Jacob Langer contributed the section on surgical management, Achille Iolascon contributed the section on molecular genetics. Paul Tittensor contributed the patient viewpoint and his comments were integrated into the final manuscript. All authors have contributed to the editing, and approved the final version which has also been approved by the BCSH General Haematology task force, and a sounding board of consultant haematologists in the UK. No financial support was received for this work. Membership of the General Haematology Task Force of BCSH at the time of publication was: Kate Ryan (Chair), Carol Briggs (Secretary), Paul Moss, Vinod Devalia, Jo Howard and Keith Hyde (NEQAS representative).

Declarations of conflicts of interest:
All authors submitted forms to the Chair of BCSH and the Chair of the General Haematology Task Force listing any sums received (either directly or funding for research or members of staff) from any organisation that could in any way gain or lose financially from the recommendations in this guideline. Having reviewed the submissions none of the authors of the guideline are considered to have a conflict of interest.
APPENDIX 1:  
The grading of evidence and the strength of recommendations is done using the ‘GRADE’ system (Grading of Recommendations Assessment, Development and Evaluation).

STRENGTH OF RECOMMENDATION

**Strong (grade 1):**  Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.

**Weak (grade 2):**  Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.

QUALITY OF EVIDENCE AND DEFINITIONS

The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what we know or our certainty.

**(A) High**  Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.

**(B) Moderate**  Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g. inconsistent results, imprecision - wide confidence intervals or methodological flaws - e.g. lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g. large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).

**(C) Low**  Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.

More information on the ‘GRADE’ system can be found at this address:  
http://www.gradeworkinggroup.org/
REFERENCES


spherocytosis: to preserve the upper or the lower pole of the spleen? *Surg Endosc*, **20**, 748-752.


Table 1: Types of mutations in membrane protein genes associated with hereditary spherocytosis and the observed membrane protein defects detected by SDS-PAGE

<table>
<thead>
<tr>
<th>Protein</th>
<th>Gene</th>
<th>Mutations detected (No. Identified)</th>
<th>Selected examples of partial protein deficiency (SDS-PAGE)</th>
<th>Primary defect in protein or gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>α Spectrin</td>
<td>SPTA1</td>
<td>Splicing/skipping (1) - SpαLEPRA allele</td>
<td>(i) α spectrin deficiency (ii) Marked deficiency of spectrin (α and β) with normal parents</td>
<td>(i) A variety of molecular defects (ii) Severe ndHS due to low expression allele SpαLEPRA inherited in trans to a SpHS allele</td>
</tr>
<tr>
<td>β Spectrin</td>
<td>SPTB</td>
<td>Null mutations (10) Nonsense or in non-coding sequence (10) Missense (5) Polymorphism (1)</td>
<td>β spectrin deficiency</td>
<td>SPTB null mutations (silencing of one β-spectrin allele)</td>
</tr>
<tr>
<td>Ankyrin</td>
<td>ANK1</td>
<td>Frameshift (17) Nonsense (8) Abnormal splicing (4) Missense (4) Promoter region (2)</td>
<td>(i) Combined spectrin and protein 4.2 deficiency (ii) Ankyrin and spectrin deficiency§ (iii) Ankyrin deficiency (recessive HS)</td>
<td>(i) missing one haploid set of ANK1 (ii) ANK1 mutations (iii) ANK1: mutations in promoter in trans to mutations in coding sequence</td>
</tr>
<tr>
<td>Band 3</td>
<td>SLC4A1</td>
<td>Missense (23) Nonsense/frameshift (18) Larger mutant protein (3) Polymorphism (5)</td>
<td>Band 3 deficiency (partial reduction of band 6 also noted in some HS)</td>
<td>Instability of mutant band 3 mRNA or inability to incorporate predicted mutant band 3 protein</td>
</tr>
<tr>
<td>Protein 4.2</td>
<td>EPB42</td>
<td>Missense (4) Nonsense or deletion (3) Splicing (2)</td>
<td>(i) Complete protein 4.2 deficiency (null phenotype) (ii) Partial protein 4.2 deficiency</td>
<td>(i) Most often EPB42 mutation (ii) Band 3 mutations resulting in loss of protein 4.2 binding site</td>
</tr>
</tbody>
</table>

Footnote:
*: Mutations have been listed (Bolton-Maggs and King 2006)
§: A reduction in ankyrin content due to ankyrin gene mutation can be masked by reticulocytosis associated with increased haemolysis in HS. Thus SDS-PAGE can not detect ankyrin deficiency in erythrocyte membranes from non-splenectomised HS patients.
**Table 2  Classification of spherocytosis and indications for splenectomy** (modified from Eber, S.W., Armbrust, R. & Schroter, W. Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility and autohemolysis. *J Pediatr*, 177, 409-411 (copyright 1990 Elsevier).)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Trait</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin (g/l)</td>
<td>Normal</td>
<td>110-150</td>
<td>80-120</td>
<td>60-80</td>
</tr>
<tr>
<td>Reticulocyte count %</td>
<td>Normal (&lt;3%)</td>
<td>3-6</td>
<td>&gt;6</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Bilirubin (micromoles/l)</td>
<td>&lt;17</td>
<td>17-34</td>
<td>&gt;34</td>
<td>&gt;51</td>
</tr>
<tr>
<td><em>Spectrin molecules per erythrocyte (% of normal)</em></td>
<td>100</td>
<td>80-100</td>
<td>50-80</td>
<td>40-60</td>
</tr>
<tr>
<td>Splenectomy</td>
<td>Not required</td>
<td>Usually not necessary during childhood and adolescence</td>
<td>Necessary during school age before puberty</td>
<td>Necessary – delay until 6 years if possible</td>
</tr>
</tbody>
</table>

*Data on spectrin content are provided for interest. This quantitation involves complex procedures. Normal (mean±SD): 226 ± 54 x10³ Sp molecules per cell.*
Table 3: Application of screening tests in the differential diagnosis of HS and other membrane-associated red cell disorders

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Osmotic fragility test</th>
<th>Acid glycerol lysis-time test</th>
<th>Osmotic gradient ektacytometry</th>
<th>Cryohemolysis Test</th>
<th>EMA binding test&lt;sup&gt;4&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>HS</td>
<td>↑ fragility</td>
<td>shortened lysis time</td>
<td>distinct HS profile</td>
<td>↑ lysis</td>
<td>↓ fluorescence</td>
</tr>
<tr>
<td>AIHA</td>
<td>↑ fragility</td>
<td>shortened lysis time</td>
<td>similar to HS</td>
<td>?</td>
<td>Normal or ↑ with some</td>
</tr>
<tr>
<td>Overhydrated HSt</td>
<td>↑ fragility&lt;sup&gt;2&lt;/sup&gt;</td>
<td>?</td>
<td>distinct profile</td>
<td>?</td>
<td>↑ fluorescence</td>
</tr>
<tr>
<td>Dehydrated HSt</td>
<td>↓ fragility&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Normal lysis&lt;sup&gt;2&lt;/sup&gt; time</td>
<td>distinct profile</td>
<td>?</td>
<td>↑ fluorescence</td>
</tr>
<tr>
<td>Cryohydrocytosis</td>
<td>?</td>
<td>?</td>
<td>distinct profile</td>
<td>?</td>
<td>↓ fluorescence</td>
</tr>
<tr>
<td>CDA type II&lt;sup&gt;1&lt;/sup&gt;</td>
<td>↑ fragility</td>
<td>?</td>
<td>?</td>
<td>Normal or ↑ with some</td>
<td>Normal or ↓ with some</td>
</tr>
<tr>
<td>SAO</td>
<td>?</td>
<td>?</td>
<td>Not deformable&lt;sup&gt;3&lt;/sup&gt;</td>
<td>↑ lysis</td>
<td>↓ fluorescence</td>
</tr>
</tbody>
</table>

?: No published data found

<sup>1</sup>: CDAII can be confirmed by molecular analysis of SEC23B (encoding COPII coat component) (Schwarz, et al 2009).

<sup>2</sup>: See the following references (Nolan 1984, Vives Corrons, et al 1995)

<sup>3</sup>: South-East Asian ovalocytosis (SAO) red cells give a virtually flat deformability profile (Ravindranath, et al 1994), indicating that these cells are rigid.

<sup>4</sup>: The EMA binding test can detect more than one sub-population of red cells in a peripheral blood sample (King, et al 2008).
Band 3 exists as both dimers and tetramers

On the cytoplasmic side of the red cell membrane, $\alpha$ spectrin binds to $\beta$ spectrin to form the $\alpha\beta$ heterodimer. The band 3 macro-complex, associated with the frequently encountered membrane abnormalities in HS, is depicted in a greater detail than the Protein 4.1R complex (consisting of GPC and Protein 4.1R) (Mohandas and Gallagher, 2008). Band 3 exists as both dimers and tetramers in the red cell membranes. Spectrin exists predominantly as tetramers in situ although higher oligomers are also present. In addition to the known band 3 tetramer-ankyrin complex, a band 3-adducin-spectrin complex has recently been identified (Anong et al., 2009)
Figure 2: Flow chart for the diagnosis of HS

Patient with haemolytic anaemia (enzymopathy and AIHA excluded)

MCV between 65fl and 90fl

Family history of HS

Clinical and laboratory features consistent for HS in proband and family. No further investigations needed

Variable clinical severity in different family members

No modifying factors found

? Co-inheritance of other red cell disorders (e.g. α or β thalassemia trait).

Modifying factor found. Further investigation of membranes not required

MCV within HS range

HS with typical features (Table IV)

Caveat: exclusion of CDAII, SAO and erythrocytosis

Erythrocyte membrane protein analysis by SDS-PAGE for protein deficiency and demonstration of abnormal band 3 in CDAII and SAO

Analyse membrane protein genes when the protein result(s) does not explain the clinical outcome and mode of inheritance. e.g. determine presence of αSpLEPA allele to confirm nond HS when αSp reduction found in index member.

The EMA binding test

Fluorescence (MCF) reading

Normal

MCF within normal range

Single peak

No membrane defect

Broad peak due to ↑RDW or twin peak

MCF > normal range

S overlap histograms of the normal and known HS to define regions of phenotypically normal RBCs and spherocytes

? residual transfused RBCs

? genuine two subpopulations of RBCs

*: Macrocytic red cells (MCV ≥ 100 fl) give MCF readings above the reference range for normal adults. The red cell disorders found to give such results are megaloblastic anaemia (Kar, et al 2010), overhydrated (OHSt) and dehydrated hereditary stomatocytosis (DHSt), antibody/cold agglutinin coated red cells, CDA type I and pyruvate kinase deficiency.

$: Overlay of fluorescence histograms is to superimpose the histograms of normal control and a known HS (from archive) on to that of the test sample. This can assist the identification of microspherocytes, spherocytes, and phenotypically normal red cells (King, et al 2008).